Edition:
United States

Compugen Ltd (CGEN.OQ)

CGEN.OQ on NASDAQ Stock Exchange Global Market

3.20USD
15 Aug 2018
Change (% chg)

$0.15 (+4.92%)
Prev Close
$3.05
Open
$3.10
Day's High
$3.25
Day's Low
$3.08
Volume
25,983
Avg. Vol
32,803
52-wk High
$5.00
52-wk Low
$2.25

Summary

Name Age Since Current Position

Paul Sekhri

60 2017 Chairman of the Board

Anat Cohen-Dayag

49 2014 President, Chief Executive Officer, Director

Ari Krashin

42 2014 Chief Financial Officer

Zurit Levine

47 2011 Vice President - Research and Discovery

John Hunter

52 2012 Vice President - Antibody Research & Development

Henry Adewoye

2018 Chief Medical Officer

Gilead Halevy

51 2018 Director

Kinneret Livnat Savitsky

51 2018 Director

Michal Preminger

2017 Director

Sanford Zweifach

61 2018 Director

Yair Aharonowitz

74 2007 Independent External Director

Ruth Arnon

84 2007 Independent Director

Arie Ovadia

68 2007 Independent External Director

Biographies

Name Description

Paul Sekhri

Mr. Paul Jai Sekhri has been appointed Director and Chairman of the Board at Compugen Ltd. effective October 2, 2017. His work experience includes the following roles: Chairman of the Board of Supervisory Directors of Pharming Group NV (from May 2016), Chief Executive Officer of Lycera Corp., Senior Vice President, Integrated Care at Sanofi, Group Executive Vice President, Global Business Development and Chief Strategy Officer at Teva Pharmaceutical Industries Ltd., has held positions in small biopharmaceutical companies, large and small pharmaceutical companies and venture capital/private equity firms, including TPG, Cerimon Pharmaceuticals, Ariad Pharmaceuticals and Novartis AG. Mr. Sekhri has over 30 years of operational experience in the life sciences sector with in-depth knowledge of multinational pharmaceutical and biotechnology markets and products. He holds a Bachelor of Science degree in Zoology from University of Maryland and has completed postgraduate studies in Clinical Anatomy and Neuroscience at School of Medicine, University of Maryland.

Anat Cohen-Dayag

Dr. Anat Cohen-Dayag, Ph.D., was named Director, President and Chief Executive Officer for Compugen Ltd. effective February 10, 2014. Dr. Anat Cohen-Dayag joined Compugen in 2002 as Director of Diagnostics, a position she held until 2005 at which time she became Vice President Diagnostic Biomarkers, a position she held until January 2007. From January 2007 until November 2008, Dr. Cohen-Dayag served as Compugen’s Vice President, Biomarkers and Drug Targets, at which point she was appointed Vice President, Research and Development. In June 2009, Dr. Cohen-Dayag was appointed, together with Mr. Martin Gerstel, as co-Chief Executive Officer of Compugen. In March 2010, upon Mr. Gerstel’s election as Chairman of the Board of Directors, Dr. Cohen-Dayag was appointed as Compugen’s President and CEO. Prior to joining Compugen, she was head of research and development and member of the Executive Management at Mindsense Biosystems Ltd. Prior to Mindsense Biosystems Ltd., Dr. Cohen-Dayag served as a scientist at the R&D department of Orgenics Ltd. Dr. Cohen-Dayag holds a B.Sc. in Biology from the Ben-Gurion University, Israel, and an M.Sc. in Chemical Immunology and a Ph.D. in Cellular Biology, both from the Weizmann Institute of Science, Israel. Additionally, Dr. Cohen-Dayag is a director of Ramot at Tel Aviv University Ltd., and a director of the IATI (Israeli Advanced Technologies Industries).

Ari Krashin

Ari Krashin is Chief Financial Officer of the Company since September, 2014. Mr. Krashin has over 15 years of experience in capital markets, finance and business development. He served as a chief financial officer for both public and private companies the most recent being AnyClip Media and Spacenet Inc. Mr. Krashin was also the CFO of Gilat Satellite Networks (Nasdaq: GILT) where he led the company's global finance and related operations, including business development, M&A activities, investor relations and administration. Mr. Krashin is a certified public accountant and began his professional career with Kesselman and Kesselman, PWC, Israel.

Zurit Levine

Dr. Zurit Levine, Ph.D., is Vice President - Research and Discovery of Compugen Ltd., since 2011. She joined Compugen in 1999 and has held several positions in Compugen’s Research & Development department. In 2004, she was appointed Director of Therapeutic Selection & Validation, which position she held until 2007 when she was appointed Director of Therapeutic Discovery. In 2009, she was appointed Executive Director of Research & Development. From January 2010 to August 2011, she held the position of Vice President, Research and Development. In August 2011 she was appointed Vice President, Research and Discovery. Dr. Levine holds a B.Sc. in Biology, an M.Sc. in Biochemistry and a Ph.D. in Biochemistry, all from the Tel Aviv University, Israel.

John Hunter

Mr. John Hunter is Vice President Antibody Research and Development of Compugen Ltd. Dr. Hunter has worked for 18 years on different aspects of oncology drug development. Following graduation from UCSF, from 1996 to 2003, Dr. Hunter worked for Millennium Pharmaceuticals Inc., where he employed genomic approaches to identify novel drug targets in lung cancer. As a founding member of Millennium’s Translational Medicine group he worked to develop clinical biomarkers for their Aurora kinase small molecule inhibitors. Following Dr. Hunter's employment at Millennium, Dr. Hunter joined Xenogen Corp., where he worked as Senior Scientist in Oncology from 2004 to 2005. Dr. Hunter later joined XOMA Ltd., where from 2005 to 2012 he managed early stage antibody discovery for multiple therapeutic programs in oncology and inflammation. Dr. Hunter currently leads therapeutic antibody research and development efforts for Compugen’s portfolio of novel oncology targets.

Henry Adewoye

Dr. Henry Adewoye is Chief Medical Officer of the Company. Dr. Adewoye joins Compugen from Gilead Sciences Inc., where he most recently served as Clinical Director in Oncology Clinical Research, was on the Oncology Leadership Team and held positions of increasing responsibility as Project Team and Clinical Lead for multiple Phase 1-3 Programs (Idelalisib - the first PI3 kinase delta inhibitor approved for relapsed CLL, SLL and Follicular lymphoma), Andecaliximab (MMP-9 inhibitor), GS-9901, and Acalisib. Prior to Gilead, he was Clinical Research Medical Director in Oncology at Amgen Inc. and Global Medical Monitor for the initial registrational trial of the bispecific antibody blinatumomab (Blincyto®) and several Phase 2 and 3 studies evaluating VEGF inhibitors (motesanib, trebananib) in patients with solid tumors. Dr. Adewoye completed his Fellowship in Hematology/Oncology at Boston Medical Center and completed his residency in Internal Medicine atMeharry Medical College. Dr. Adewoye received his medical degree at the University of Jos,Nigeriaand Fellowship training in hematology and laboratory medicine at the University College Hospital Ibadan,Nigeria. Dr Adewoye is Board Certified by the American Board of Internal Medicine in Medical Oncology, Hematology and Internal Medicine.

Gilead Halevy

Mr. Gilead Halevy has been appointed Director at Compugen Ltd. effective June 11, 2018. His work experience includes the following roles: Chairman of the Board of Brand Industries Ltd., Carmor Integrated Solutions Ltd., Carmel Wineries, Continuity Software Ltd. and S.AL Holdings., Founding Member and General Partner of Kedma Capital Partners (since 2006) and Head of Giza Venture Capital’s European business activities 92001-2006). Mr. Halevy holds a Bachelors degree in Humanities and a LLB degree, both from The Hebrew University of Jerusalem.

Kinneret Livnat Savitsky

Dr. Kinneret Livnat Savitsky has been appointed Director at Compugen Ltd. effective June 11, 2018. Dr. Livnat Savitsky's work experience includes the following roles: Vice President - Biology, Research & Development at the Company (2000-2004), Interim Chief Executive Officer and Board Member of FutuRx Ltd., Director at various companies, Consultant and Chief Executive Officer at BioLineRx Ltd. (2010-2016). Dr. Livnat Savitsky holds a Bachelor of Science degree in Biochemistry from Tel Aviv University, a Bachelor of Science degree in Biology from The Hebrew University of Jerusalem and a Master of Science degree and a Doctorate of Science degree, both in Human Genetics from Tel Aviv University.

Michal Preminger

Dr. Michal Preminger, Ph.D. is Director of the company. She brings to Compugen broad managerial and business experience focused on the pharma and biotech industries. At Harvard Office of Technology Development, she has negotiated a multitude of licensing and strategic alliance agreements with pharmaceutical and biotechnology companies and supported the launch of many biotechnology startups. Prior to joiningHarvardin 2005, Dr. Preminger held a number of senior executive business development and R&D positions in technology and biotechnology companies, including at Compugen, where she was a member of the management team that took the Company public inAugust 2000. Dr. Preminger is a member of the board of directors of BioArray Genetics and Israel Brain Technologies, and a member of the Scientific Advisory Board at FutuRx (a partnership between Takeda Pharmaceuticals, Johnson & Johnson and Orbimed Ventures) and Prize4Life.

Sanford Zweifach

Mr. Sanford (Sandy) Zweifach has been appointed Director at Compugen Ltd. effective June 11, 2018. His work experience includes the following roles: Founder and Chief Executive Officer of Nuvelution Pharma, Inc. (since 2015), Founder and Chief Executive Officer of Ascendancy Healthcare, Inc., Partner at Reedland Capital Partners (2005-2010), Chief Executive Officer of Pathways Diagnostics, Managing Director and Chief Financial Officer of Bay City Capital, President and Chief Financial Officer of Epoch Biosciences, Chairman of Lyric Pharmaceuticals Inc. and IMIDomics, S.L. and Director of Realm Therapeutics, Inc. He holds a Bachelor of Science degree in Biology from University of California San Diego and a Master of Science degree in Physiology from University of California, Davis. He is a Certified Public Accountant.

Yair Aharonowitz

Prof. Yair Aharonowitz, Ph.D., serves as Independent External Director of Compugen Ltd., since July 2007. He is a Professor (Emeritus) of Microbiology and Biotechnology at Tel Aviv University (TAU). He was a visiting scientist at Oxford University, an Alberta Heritage Fellow at the University of Alberta, Edmonton, and a visiting professor at the Karolinska Institute and at the University of British Columbia. Professor Aharonowitz’s research interests include the molecular genetics and biosynthesis of antibiotics, molecular biology of microbial pathogens and the development of new targets for new antibiotics. He served as TAU Vice President and Dean for R&D (1997-2001), Chairman of the Department of Microbiology and Biotechnology and Chairman of the Institute of Biotechnology and served as a member of the TAU Executive Council. He served as the Chairman of Ramot Fund for Applied Research, as a member of TAU committee for strategic planning, on the TAU patent committee and was a member of the National Committee for Biotechnology. He is a Fellow of the American Academy of Microbiology.

Ruth Arnon

Prof. Ruth Arnon serves as Independent Director of Compugen Ltd., since May 2007. Formerly the Vice-President of the Weizmann Institute of Science (1988-1997), she is a noted immunologist, having joined the Institute in 1960. She served as Head of the Department of Chemical Immunology, Dean of the Faculty of Biology and Director of the Institute's MacArthur Center for Molecular Biology of Tropical Diseases. Prof. Arnon has made significant contributions to the fields of vaccine development, cancer research and to the study of parasitic diseases. Along with Prof. Michael Sela, she developed Copaxone® a drug for the treatment of multiple sclerosis which is presently marketed worldwide. Prof. Arnon is a member of the Israel Academy of Sciences and presently serves as its President. She is an elected member of the European Molecular Biology Organization, served as President of the European Federation of Immunological Societies and as Secretary-General of the International Union of Immunological Societies. Her awards include the Robert Koch Prize in Medical Sciences, Spain's Jiminez Diaz Memorial Prize, France's Legion of Honor, the Hadassah World Organization's Women of Distinction Award, the Wolf Prize for Medicine, the Rothschild Prize for Biology, the Israel Prize and she received an Honorary Doctorate from Ben-Gurion University and from Tel Aviv University. In addition, Prof. Arnon is the incumbent of the Paul Ehrlich Chair in Immunochemistry at the Weizmann Institute.

Arie Ovadia

Dr. Arie Ovadia serves as Independent External Director at Compugen Ltd., since July, 2007. He advises major Israeli companies on finance, accounting and valuations, and is a member of the Board of Directors of several corporations, including Strauss Ltd., Israel Petrochemical Industries Ltd., Bazan Ltd., Maxtech Technologies Ltd., and Elron Electronic Industries Ltd. He has taught at New York University, Temple University and, in Israel, at Tel Aviv and Bradford Universities and The College of Management. Dr. Ovadia served as a member of the Israeli Accounting Board, and is a 14-year member of the Israel Securities Authority. Dr. Ovadia holds an undergraduate degree and an MBA from Tel Aviv University, and earned his Ph.D. in economics from the Wharton School at the University of Pennsylvania.